IBDEI0FS ; ; 18-NOV-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;NOV 18, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,21202,0)
 ;;=281.1^^137^1229^110
 ;;^UTILITY(U,$J,358.3,21202,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21202,1,4,0)
 ;;=4^281.1
 ;;^UTILITY(U,$J,358.3,21202,1,5,0)
 ;;=5^Vit B12 Deficiency(Dietary)
 ;;^UTILITY(U,$J,358.3,21202,2)
 ;;=^267974
 ;;^UTILITY(U,$J,358.3,21203,0)
 ;;=286.7^^137^1229^44
 ;;^UTILITY(U,$J,358.3,21203,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21203,1,4,0)
 ;;=4^286.7
 ;;^UTILITY(U,$J,358.3,21203,1,5,0)
 ;;=5^Coagulation Defect(Any),Acquired
 ;;^UTILITY(U,$J,358.3,21203,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,21204,0)
 ;;=289.9^^137^1229^106
 ;;^UTILITY(U,$J,358.3,21204,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21204,1,4,0)
 ;;=4^289.9
 ;;^UTILITY(U,$J,358.3,21204,1,5,0)
 ;;=5^Thrombocytosis, Essential
 ;;^UTILITY(U,$J,358.3,21204,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,21205,0)
 ;;=451.9^^137^1229^107
 ;;^UTILITY(U,$J,358.3,21205,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21205,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,21205,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,21205,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,21206,0)
 ;;=446.6^^137^1229^108
 ;;^UTILITY(U,$J,358.3,21206,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21206,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,21206,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(Ttp)
 ;;^UTILITY(U,$J,358.3,21206,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,21207,0)
 ;;=286.4^^137^1229^111
 ;;^UTILITY(U,$J,358.3,21207,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21207,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,21207,1,5,0)
 ;;=5^Von Willebrand'S Disease
 ;;^UTILITY(U,$J,358.3,21207,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,21208,0)
 ;;=204.00^^137^1229^4
 ;;^UTILITY(U,$J,358.3,21208,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21208,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,21208,1,5,0)
 ;;=5^All, W/O Remission
 ;;^UTILITY(U,$J,358.3,21208,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,21209,0)
 ;;=204.01^^137^1229^3
 ;;^UTILITY(U,$J,358.3,21209,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21209,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,21209,1,5,0)
 ;;=5^All, In Remission
 ;;^UTILITY(U,$J,358.3,21209,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,21210,0)
 ;;=204.10^^137^1229^41
 ;;^UTILITY(U,$J,358.3,21210,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21210,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,21210,1,5,0)
 ;;=5^Cll, W/O Remission
 ;;^UTILITY(U,$J,358.3,21210,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,21211,0)
 ;;=204.11^^137^1229^40
 ;;^UTILITY(U,$J,358.3,21211,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21211,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,21211,1,5,0)
 ;;=5^Cll, In Remission
 ;;^UTILITY(U,$J,358.3,21211,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,21212,0)
 ;;=201.90^^137^1229^71
 ;;^UTILITY(U,$J,358.3,21212,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21212,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,21212,1,5,0)
 ;;=5^Hodgkin'S Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,21212,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,21213,0)
 ;;=785.6^^137^1229^77
 ;;^UTILITY(U,$J,358.3,21213,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21213,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,21213,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,21213,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,21214,0)
 ;;=200.20^^137^1229^78
 ;;^UTILITY(U,$J,358.3,21214,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21214,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,21214,1,5,0)
 ;;=5^Lymphoma, Burkitt'S, Unspecified Sites
 ;;^UTILITY(U,$J,358.3,21214,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,21215,0)
 ;;=202.00^^137^1229^80
 ;;^UTILITY(U,$J,358.3,21215,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21215,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,21215,1,5,0)
 ;;=5^Lymphoma, Low-Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,21215,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,21216,0)
 ;;=200.10^^137^1229^79
 ;;^UTILITY(U,$J,358.3,21216,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21216,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,21216,1,5,0)
 ;;=5^Lymphoma, Int Or High Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,21216,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,21217,0)
 ;;=273.3^^137^1229^81
 ;;^UTILITY(U,$J,358.3,21217,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21217,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,21217,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,21217,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,21218,0)
 ;;=203.00^^137^1229^90
 ;;^UTILITY(U,$J,358.3,21218,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21218,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,21218,1,5,0)
 ;;=5^Multiple Myeloma W/O Rem
 ;;^UTILITY(U,$J,358.3,21218,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,21219,0)
 ;;=203.01^^137^1229^89
 ;;^UTILITY(U,$J,358.3,21219,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21219,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,21219,1,5,0)
 ;;=5^Multiple Myeloma In Remission
 ;;^UTILITY(U,$J,358.3,21219,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,21220,0)
 ;;=238.6^^137^1229^93
 ;;^UTILITY(U,$J,358.3,21220,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21220,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,21220,1,5,0)
 ;;=5^Plasmacytoma Nos
 ;;^UTILITY(U,$J,358.3,21220,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,21221,0)
 ;;=205.00^^137^1229^6
 ;;^UTILITY(U,$J,358.3,21221,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21221,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,21221,1,5,0)
 ;;=5^Aml, W/O Remission
 ;;^UTILITY(U,$J,358.3,21221,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,21222,0)
 ;;=205.01^^137^1229^5
 ;;^UTILITY(U,$J,358.3,21222,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21222,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,21222,1,5,0)
 ;;=5^Aml, In Remission
 ;;^UTILITY(U,$J,358.3,21222,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,21223,0)
 ;;=205.10^^137^1229^43
 ;;^UTILITY(U,$J,358.3,21223,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21223,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,21223,1,5,0)
 ;;=5^Cml, W/O Remission
 ;;^UTILITY(U,$J,358.3,21223,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,21224,0)
 ;;=205.11^^137^1229^42
 ;;^UTILITY(U,$J,358.3,21224,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21224,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,21224,1,5,0)
 ;;=5^Cml, In Remission
 ;;^UTILITY(U,$J,358.3,21224,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,21225,0)
 ;;=289.0^^137^1229^45
 ;;^UTILITY(U,$J,358.3,21225,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21225,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,21225,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,21225,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,21226,0)
 ;;=238.4^^137^1229^94
 ;;^UTILITY(U,$J,358.3,21226,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21226,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,21226,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,21226,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,21227,0)
 ;;=V58.61^^137^1229^112
 ;;^UTILITY(U,$J,358.3,21227,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21227,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,21227,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,21227,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,21228,0)
 ;;=282.49^^137^1229^104
 ;;^UTILITY(U,$J,358.3,21228,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21228,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,21228,1,5,0)
 ;;=5^Thalassemia Nec
 ;;^UTILITY(U,$J,358.3,21228,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,21229,0)
 ;;=289.89^^137^1229^13
 ;;^UTILITY(U,$J,358.3,21229,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21229,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,21229,1,5,0)
 ;;=5^Blood Diseases Nec
 ;;^UTILITY(U,$J,358.3,21229,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,21230,0)
 ;;=238.79^^137^1229^76
 ;;^UTILITY(U,$J,358.3,21230,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21230,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,21230,1,5,0)
 ;;=5^LYMPH/HEMATPOITC TIS NEC
 ;;^UTILITY(U,$J,358.3,21230,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,21231,0)
 ;;=287.30^^137^1229^95
 ;;^UTILITY(U,$J,358.3,21231,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21231,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,21231,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,21231,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,21232,0)
 ;;=288.09^^137^1229^2
 ;;^UTILITY(U,$J,358.3,21232,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21232,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,21232,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,21232,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,21233,0)
 ;;=V10.21^^137^1229^51
 ;;^UTILITY(U,$J,358.3,21233,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21233,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,21233,1,5,0)
 ;;=5^H/O Laryngeal Cancer
 ;;^UTILITY(U,$J,358.3,21233,2)
 ;;=^295214
 ;;^UTILITY(U,$J,358.3,21234,0)
 ;;=284.2^^137^1229^91
 ;;^UTILITY(U,$J,358.3,21234,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21234,1,4,0)
 ;;=4^284.2
 ;;^UTILITY(U,$J,358.3,21234,1,5,0)
 ;;=5^Myelophthisic Anemia
 ;;^UTILITY(U,$J,358.3,21234,2)
 ;;=^334037
 ;;^UTILITY(U,$J,358.3,21235,0)
 ;;=202.40^^137^1229^64
 ;;^UTILITY(U,$J,358.3,21235,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21235,1,4,0)
 ;;=4^202.40
 ;;^UTILITY(U,$J,358.3,21235,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspecified site
 ;;^UTILITY(U,$J,358.3,21235,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,21236,0)
 ;;=287.49^^137^1229^105
 ;;^UTILITY(U,$J,358.3,21236,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21236,1,4,0)
 ;;=4^287.49
 ;;^UTILITY(U,$J,358.3,21236,1,5,0)
 ;;=5^Thrombocytopenia,Drug Induced
 ;;^UTILITY(U,$J,358.3,21236,2)
 ;;=^339610
 ;;^UTILITY(U,$J,358.3,21237,0)
 ;;=465.9^^137^1230^67
 ;;^UTILITY(U,$J,358.3,21237,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21237,1,4,0)
 ;;=4^465.9
 ;;^UTILITY(U,$J,358.3,21237,1,5,0)
 ;;=5^URI
 ;;^UTILITY(U,$J,358.3,21237,2)
 ;;=URI^269878
 ;;^UTILITY(U,$J,358.3,21238,0)
 ;;=462.^^137^1230^58
 ;;^UTILITY(U,$J,358.3,21238,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21238,1,4,0)
 ;;=4^462.
 ;;^UTILITY(U,$J,358.3,21238,1,5,0)
 ;;=5^Sore Throat
